Minium

Quick links to important sections

Minium

Method of action: Other Nervous System Drugs

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Minium

Quick Facts

Property Description
Active ingredient Flunarizine
Form Oral Tablet or Capsule
Pharmacological class Selective Calcium Channel Blocker
Common use Prevention of Migraine and Vertigo
Origin Synthetic

What is Minium and What Class of Medicine Does It Belong To?

Minium is a prescription medicine taken by mouth, used primarily for preventive treatment. The drug's core active ingredient is Flunarizine, which is a synthetic compound.

Minium is classified as a Selective Calcium Entry Blocker and belongs to the broader group of Calcium Channel Blockers. This synthetic drug is intended for oral administration and is typically provided in the form of tablets or capsules. Flunarizine is used in the management of vestibular disorders. Minium is a single-ingredient product known to be clinically recognized for its long-standing use in neurological prophylaxis across various international markets.


What is the General Purpose of Minium?

The general purpose of Minium is prophylaxis, meaning it is used to reduce the frequency and severity of future episodes, rather than to treat symptoms once they occur. It is taken on a long-term, continuous basis to provide ongoing protection against debilitating attacks.

Minium is primarily used for the prevention of migraine headaches. The medicine is utilized to reduce the frequency of migraine attacks in adult patients. A common use scenario is for patients experiencing frequent, debilitating migraines. A secondary general use relates to relieving the persistent symptoms of vertigo (dizziness) that are linked to inner ear imbalances.


Why is Minium Called a Selective Calcium Blocker?

Minium is called a selective blocker because it primarily targets specific calcium channels involved in processes related to migraine and vascular tone, without significantly affecting others. This key feature is the basis of its mechanism principle: it helps stabilize cell membranes and provides a degree of vessel protection against the exaggerated constricting and widening that can trigger an attack. This selective action allows it to focus its effects, making the brain less prone to chaotic reactions without broadly interfering with essential cardiovascular functions like a non-selective calcium channel blocker would. This characteristic differentiation is what separates flunarizine from many older calcium channel antagonists.

Regulatory References

  1. NIH Reference
  2. National Institutes of Health (NIH)

What side effects are possible with Minium?

Possible Side Effects and Safety Information

The adverse reactions and safety characteristics associated with Minium (Flunarizine) are documented based on clinical trials and post-marketing experience as classified by national regulatory authorities. The official safety profile is strictly defined by System Organ Classes and frequency categories.

Classification of Officially Documented Side Effects

The most frequently reported adverse reactions, categorized as Very Common (occurring in ge 1/10 of patients), are Weight Increased and Somnolence (drowsiness). Reactions classified as Common (occurring in ge 1/100 to <1/10 of patients) include Increased Appetite, Depression, Insomnia, Fatigue, and various Gastrointestinal Disorders (such as Constipation and Nausea). Additionally, Myalgia and effects on the Reproductive System (Menstruation Irregular, Breast Pain) are noted as common adverse events.

Frequency Category Key Adverse Reactions (System Class)
Very Common Weight Increased (Metabolism), Somnolence (Nervous System)
Common Depression (Psychiatric), Increased Appetite (Metabolism), Fatigue (General)

Serious Adverse Reactions and Special Safety Considerations

Official regulatory documents highlight the potential for serious reactions related to the central nervous system. These include the development of Extrapyramidal Symptoms (e.g., Parkinsonism, tremor, gait disturbance) and Depression, which, if severe, may lead to discontinuation of the medicine. The frequency of Extrapyramidal Disorder is classified as Not Known.

Safety notes for specific populations and conditions are documented in the labeling. Older Adults (aged ge 65) are cited as being at a particular risk for developing Extrapyramidal Symptoms. The medicine is contraindicated in individuals with a history of depressive illness or pre-existing Parkinson's disease. Monitoring is required during maintenance treatment for the onset of serious symptoms. Excessive sedation can result from concurrent use with substances such as alcohol or hypnotics.

Overdose and Emergency Response

Minium Overdose and When to Seek Help

The official regulatory profile for Minium (Flunarizine) overdose is defined by documented clinical manifestations and mandatory emergency actions, establishing when urgent medical help is required.

Acute overdosage, with cases reported at doses up to 600 mg in one intake, is officially associated with specific symptoms. The manifestations documented in regulatory sources include central nervous system effects such as sedation and agitation. A key cardiovascular sign listed is tachycardia (rapid heart rate). Furthermore, asthenia (physical weakness or fatigue) is an expected finding based on the pharmacological properties of the drug.

Urgent medical attention must be sought for any suspected overdosage. The regulatory label explicitly states that no specific antidote is known, thus making the management framework reliant on non-specific measures. Officially described supportive procedures include gastric lavage (stomach washing) and the administration of charcoal. General supportive measures are required to address the documented central nervous system and cardiovascular effects following acute exposure. No distinct population-specific overdose considerations are explicitly detailed in the official prescribing information.

Therapeutic Uses of Minium

What Minium Treats: Main Uses and Benefits

Minium is commonly used in the management of neurological and vestibular disorders to provide prophylactic (preventive) support. The medication is utilized as a prophylactic measure for managing migraine and symptoms related to vertigo of central and peripheral origin.

It is applied in addressing the recurring symptom pattern of intense, throbbing, and debilitating headaches and may assist in managing the overall symptom load related to migraine episodes, which involves addressing their frequency, severity, and duration. For patients with vestibular symptoms, the medication helps address the distressing cluster of symptoms characterized by persistent feelings of dizziness and spinning. This supportive benefit is considered relevant for adult patients, and sometimes pediatric patients, where symptoms interfere with daily functioning and stability.

“The general patient-oriented benefit is the support it offers for managing these chronic symptoms.”

Quick Fact: Relief for Key Symptom Clusters
Prophylactic Domain Supports the easing of headache frequency and severity
Vestibular Domain Relevant for managing chronic dizziness and spinning sensations

Regulatory References

  1. NIH National Library of Medicine

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Minium

The following information details the official population eligibility and non-eligibility for Minium (Flunarizine), based strictly on regulatory documents.

Eligibility Category Status as Stated in Regulatory Labels
Populations for whom use is allowed Adults aged 18 years and older for the licensed indications.
Populations for whom use is contraindicated Patients with a current depressive illness or a history of recurrent depression. Patients with pre-existing Parkinson’s Disease or other extrapyramidal disorders. Known hypersensitivity to flunarizine or excipients.
Populations for whom use is not recommended Children under 12 years of age (safety and efficacy are not established). Pregnant women (unless benefits outweigh risks). Breastfeeding women (contraindicated/not recommended).
Age-Related Eligibility Condition-Specific Rules
Adults (18-64): Licensed for use. Hepatic Impairment: Use requires caution due to liver metabolism, often necessitating a lower starting dose.
Older Adults (65+): Use requires special caution and regular monitoring for depressive or extrapyramidal symptoms. Renal Impairment: No major restriction is typically cited in core labels.

Official Eligibility Statements:

  • The medicine is contraindicated in specific patient groups defined by a history of movement disorders or psychiatric illness.
  • Use is not recommended for the pediatric population under 12 years, for pregnant women, and for women who are breastfeeding.
  • Conditional use is imposed for older adults and patients with hepatic impairment, requiring close monitoring and potential discontinuation if specific clinical changes occur.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Minium


Interaction Scope

  • Medicinal product categories with documented interactions: CNS Depressants, Hepatic Enzyme Modifiers, Anti-hypertensive Agents, Oral Hormonal Contraceptives.
  • Specific interacting medicines (if explicitly listed): Carbamazepine, Phenytoin, Topiramate, Digoxin.
  • Mechanistic basis of interactions (only if stated in label): Pharmacokinetic interaction via Hepatic enzyme induction (reduced exposure) and CYP2D6 inhibition (increased plasma); Pharmacodynamic additive effects (sedation/hypotension).
  • Timing-based interaction rules (if applicable): None documented.
  • Population-specific interaction notes (if applicable): Co-administration with Digoxin is documented as safe in elderly patients.
  • Interaction-related restrictions: Substance restriction against alcohol due to enhanced sedation.

Interaction Classifications (High-Level)

  • Interaction severity classification (as defined in official documents): Clinically significant interactions exist for co-administration with CNS depressants and enzyme-modifying drugs.
  • Regulatory basis (EMA / FDA / etc.): Based on official prescribing information, including the Summary of Product Characteristics and FDA-aligned regulatory documents.
  • Interaction-context constraints (as defined in official documents): Enzyme inducers reduce Minium exposure; CYP2D6 inhibitors increase Minium’s plasma concentration.

Resulting Interaction Structure

  • Official interaction statements:
    • Co-administration with CNS Depressants leads to enhanced sedative effects. Hepatic enzyme inducers (e.g., Carbamazepine, Phenytoin) cause reduced systemic exposure. CYP2D6 inhibitors cause an increase in plasma concentration. Anti-hypertensive Drugs may potentiate hypotensive effects. Alcohol is noted to increase drowsiness and is advised against. Oral Hormonal Contraceptives are linked to observed galactorrhoea in regulatory reports.
  • Connection to the overall interaction profile (2–4 sentences): Regulatory documents define Minium’s profile by focusing on pharmacokinetic changes related to the CYP2D6 pathway, which alters drug exposure. The second constraint is the additive pharmacodynamic effect with CNS depressants and alcohol, which limits simultaneous use due to enhanced sedation.

Mechanism of Action

The mechanism of Minium (Flunarizine) involves multi-target modulation that influences cellular excitability and cerebrovascular function. The mechanism requires reaching a stable concentration in the central nervous system ( CNS) to fully engage its targets.

Stabilizing Neuronal Excitability

Minium acts as a blocker of specific Voltage-Dependent Calcium Channels ( CaV), primarily the T-type channels ( CaV3. x) found on CNS neurons. Inhibiting the pathological influx of Ca^2+ ions elevates the threshold for cellular hyperexcitability and depolarization, resulting in a state of cellular membrane stabilization.

Modulating Vascular Tone and Balance Signals

The drug complements its Ca^2+ channel blockade by functioning as an antagonist at several critical receptor sites, including the Histamine H1 and Serotonin 5HT2 A receptors. H1 antagonism suppresses signal transmission within the balance-regulating vestibular system, while 5HT2 A antagonism modulates exaggerated fluctuations in cerebral blood vessel constriction and dilation.

Chronic Mechanism and Time Dependence

The mechanism requires chronic engagement and is dependent on the sustained action of the molecule engaging its targets over a long period. This mechanism establishes a state of chronic physiological modulation of instability; it lacks the mechanistic kinetics to reverse established acute physiological cascades.

Dosage and Administration Information

How Minium is Used

Minium (Flunarizine) is administered via the oral route as a tablet or capsule, following a prophylactic usage pattern. The dose is typically taken once daily at night or in the evening. This specific timing is used for proper administration. The medicine can be taken with or without food.


Official Dosing and Treatment Cycles

The usage protocol is structured around a defined trial period followed by an intermittent maintenance schedule. Dosing recommendations generally align with the following principles:

  • Initial Treatment (Adults < 65): The standard initial dose is 10 mg once daily. This phase typically lasts for two months to assess response. If significant improvement is not observed after this trial period, the treatment is discontinued.
  • Maintenance Treatment: Responders transition to a cyclic pattern of administration, involving five consecutive days of treatment at the daily dose, followed by two successive medicine-free days. Maintenance is interrupted after a period of six months and only restarted upon symptom relapse.
  • Maximum Dose: The maximum daily dose should not exceed 10 mg.

Population-Specific Use Adjustments

Instructions define specific starting doses for certain patient groups:

  • Older Adults (65 years and older): The initial daily dose is 5 mg once daily.
  • Pediatric Patients (12 years and older): The starting dose is 5 mg daily. This dose may be increased to 10 mg for patients weighing over 40 kg.
  • Hepatic Impairment: Treatment initiation starts at a dose of 5 mg daily.

This structured approach defines the administration, frequency, and duration limits, ensuring the medicine is used procedurally as prescribed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Minium

Evidence for use in Preventing Migraine Headaches

Minium (Flunarizine) was studied for the conditions it is intended to address, which are characterized by fluctuating or episodic manifestations (migraine prophylaxis). The majority of the evidence comes from Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These studies primarily included adults with recurrent episodic migraine and often compared Minium to an inactive pill (placebo) or to other active comparator medicines. Researchers monitored several outcomes related to physical discomfort, including the mean number of migraine attacks recorded per month and the change in headache intensity.

In these trials, participants were observed in studies over short periods, typically between 3 and 4 months. The research highlights changes measured during the study period where groups taking Minium registered lower monthly migraine frequency compared to their original baseline measurements. However, many of the pivotal trials supporting this body of evidence are older, and some evidence quality varies across studies. As a result, the research may not align perfectly with contemporary trial standards.

Evidence for use in Preventing Chronic Vertigo Symptoms

Minium was evaluated in research contexts involving fluctuating or unstable symptoms of chronic spinning and dizziness linked to vestibular imbalances. The body of evidence for this specific indication is less numerous than the research available for migraine prevention. The research includes some RCTs and systematic reviews that examined prophylactic treatments for vestibular disorders.

Researchers examined outcomes related to systemic or functional imbalance, such as the frequency and severity of vertiginous episodes, and also patient-reported outcomes describing perceived discomfort related to dizziness and instability.

Evidence is limited for this indication. Regulatory assessments have noted that the data for conditions where symptoms may vary in intensity is restricted by the small sample sizes of most studies. This means the certainty remains low for this specific clinical use, and findings were often mixed or inconsistent across the different small-scale investigations.

What is Still Uncertain About Minium's Research Base

A critical assessment of the research available for Minium highlights several areas where data are currently limited. The certainty remains low for the use of Minium in managing chronic vertigo symptoms, largely due to a lack of recent, large-scale, placebo-controlled trials. Also, as follow-up durations were limited in many studies, long-term effects are not fully established, leaving questions about the patterns of symptom change over time. The results apply only to the populations studied, and there is limited information on how the medicine was observed in certain groups, such as older adults.

Key Studies & References

  1. Flunarizine MeSH entry (NIH National Library of Medicine)

Frequently Asked Questions (FAQ)

Common questions about Minium (FAQ)


Q: How quickly do official sources say Minium starts working?

Official patient information indicates that the full beneficial effect of Minium may not be noticeable immediately. It may take several weeks for the full prophylactic benefit to be assessed, with some clinical information suggesting a timeframe of six to twelve weeks.


Q: How long does the effect of Minium typically last?

According to regulatory documents, the terminal elimination half-life (the time estimated for half the medicine to be cleared from the bloodstream) of Minium is highly variable, generally ranging from 5 to 15 hours after a single dose. However, due to its deep distribution in the body, measurable concentrations can persist in the plasma for up to 30 days.


Q: What should I know about using Minium for an extended period?

Official guidelines describe that continuous treatment is often interrupted after a period of six months and should only be restarted if symptoms return. It is noted that patients should undergo regular monitoring by a healthcare professional throughout the treatment period to assess for possible adverse effects.


Q: Is a headache a reported side effect of Minium?

Headache is the condition Minium is used to address. Official regulatory tables summarizing the most frequent adverse reactions (side effects) of the medicine do not list headache as a commonly reported adverse event.


Q: What do studies say about the use of Minium in older adults?

Use in older adults (aged 65 years and older) is subject to special caution, as official documents recommend a reduced starting dose and close monitoring. This is due to a heightened risk in this population for central nervous system issues like extrapyramidal symptoms (movement disorders) or depression.


Q: Are there different strengths or forms (like tablets vs. liquid) of Minium?

Minium is officially supplied for oral use in the form of tablets or capsules. The medicine is commonly available in two standard strengths, 5 mg and 10 mg.


Q: What is the difference between Minium and other similar medicines?

Minium is classified as a selective calcium channel blocker. Regulatory documents indicate that its selective nature and its ability to act within the central nervous system (CNS) are key features that distinguish it from some other, non-selective calcium channel blockers.


Q: Are there foods or supplements that are known to interact with Minium?

Official patient information states that Minium can be taken with or without food. Regulatory documents generally do not list specific food products that are known to interfere with the medicine.


Q: Why do some people refer to Minium by a different name?

Minium is a brand name for the core active ingredient, Flunarizine. People may refer to the medicine by its generic name, Flunarizine, or by other brand names used in various international markets, such as Sibelium.


Q: Does the official product information for Minium address driving or operating machinery?

Yes, official safety warnings state that Minium may cause drowsiness or sedation, especially when starting treatment. Therefore, official product information states that operating a vehicle or machinery should be avoided.


Q: How long after stopping Minium is the drug generally thought to leave the body?

Due to its mechanism, which allows the medicine to distribute throughout the body, measurable concentrations of Minium may persist in the body for up to 30 days after the final dose, even though the elimination half-life is described as significantly shorter.


Q: Do any official warnings exist about stopping Minium suddenly?

Official patient information generally advises against stopping Minium suddenly, particularly if the medicine has been taken for several weeks or months. Decisions regarding discontinuing treatment are to be discussed with a healthcare professional.


Q: Does Minium interact with any common herbal remedies?

Official labels do not list specific interactions with herbal remedies. However, official guidance indicates that individuals are to report all supplements and herbal products being used to a healthcare professional.


Q: Does the effectiveness of Minium change over time with continued use?

Studies and official information suggests that Minium can continue to provide prophylactic benefit for up to 12 months in patients who respond to treatment. However, regular review by a doctor is required to assess continued treatment success and safety.


Q: Do official documents mention any potential for skin reactions with Minium?

Official reporting includes certain skin reactions, such as skin rash or allergic skin reaction, as documented adverse events associated with the use of Minium.


Q: Can Minium be split or crushed?

Official product information does not generally provide instructions to split or crush Minium tablets. When a tablet is not scored, general guidance often suggests that the tablet should not be divided, as this can potentially affect the dose received.


Q: Does Minium require regular blood tests or monitoring?

Official guidance requires regular clinical monitoring by a doctor for the onset of specific adverse reactions, such as depression or movement disorders. There are no general regulatory requirements for mandatory blood tests associated with this medicine.


Q: Is Minium used in other countries besides the US and Europe?

Yes, regulatory documents indicate that Minium is licensed and marketed in many international markets. While it is not approved for use in the United States, official sources confirm its regulatory status in countries across Europe, Asia, and other regions.


Q: What type of medical professional typically prescribes Minium?

The authority to prescribe Minium rests with a licensed prescriber. This professional may be a specialist or a general practitioner (GP), depending on the specific country or region and the clinical needs of the individual patient.


Q: Do official materials specify what to do about a missed dose?

Official guidance advises that if a dose is forgotten, it should be remembered, unless it is almost time for the next scheduled dose. In that case, the missed dose is typically skipped, and the official materials specify that a double dose is not to be taken to compensate.


Q: How does Minium affect the liver?

Minium is primarily metabolized, or broken down, by the liver. Official guidance states that caution and a lower starting dose may be required for individuals with pre-existing liver problems (hepatic impairment) due to the drug’s clearance pathway.


Q: Does Minium contain any ingredients that cause allergic reactions?

Minium is contraindicated for patients with known hypersensitivity (severe allergic reaction) to the active ingredient, flunarizine, or to any of the non-active ingredients, known as excipients. For instance, official documents list lactose monohydrate as an excipient.


How should Minium be stored and disposed of?

How to Store and Dispose of Minium (Flunarizine)

Official regulatory documentation details mandatory conditions for the storage and disposal of Minium tablets or capsules.

Storage Requirements

Minium must be stored at room temperature, typically between 15°C and 30°C. The product requires protection from light and must be kept in a dry place to avoid moisture. It must remain in its original container with the lid or seal tightly closed.

Child Safety: The medicine must be kept locked away and out of the reach of children and pets.

Disposal Instructions

To prevent environmental contamination, unused or expired Minium must not be flushed down the toilet or disposed of in domestic wastewater. The product must be returned to a pharmacist or designated collection point for disposal in accordance with local, regional, and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Minium found in:

A-Z Index: